Superworth

Adma Biologics EV/EBIT ADMA

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2024.

Today, Nov 2, 2026
11.3×
3-year median
28.8×
Against its 3-year history
18th
percentile: 0 is its lowest day, 100 its highest
3-year range
8.9× to 76.0×
Peer median
23.8×

Adma Biologics' EV/EBIT is 11.3× as of Nov 2, 2026.

That is below its 3-year median of 28.8×, lower than on 82% of days in the last 3 years.

Over that time it ranged from 8.9× in Jun 2026 to 76.0× in May 2024.

The median for 10 biotech stocks of a similar size is 23.8×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far11.3×8.9×25.6×
202527.5×20.8×40.0×
202436.1×36.0×76.0×

Against its peers

Companies in Biotechnology nearest Adma Biologics' size, closest first, today.

CompanyEV/EBIT
ADMAAdma Biologics11.3×
VCELVericel110×
MGTXMeiraGTx4.7×
KRYSKrystal Biotech40.1×
RGENRepligen156×
TECHBIO-TECHNE45.0×
HALOHalozyme Therapeutics17.8×
NBIXNeurocrine Biosciences18.6×
EXELExelixis16.8×
ALNYAlnylam Pharmaceuticals19.2×
INCYIncyte28.3×
Peer median23.8×

Where Adma Biologics ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Adma Biologics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.